Precious Metals

[gfp927z]

>>> Gilead's Kite and Sangamo Therapeutics to collaborate on engineered cell therapies for cancer


By Ciara Linnane

Feb 22, 2018


https://www.marketwatch.com/story/gileads-kite-and-sangamo-therapeutics-to-collaborate-on-engineered-cell-therapies-for-cancer-2018-02-22-7912758


Gilead Sciences Inc.'s unit Kite has entered an agreement with Sangamo Therapeutics Inc. SGMO, +14.41% to collaborate in developing engineered cell therapies to treat cancer. Under the terms of the deal, Kite will use Sangamo's zine finger nuclease technology platform to develop the next-generation therapies for autologous and allogeneic use in treating different cancers. "Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients," the companies said in a statement. Sangamo will receive $150 million in upfront payments and be entitled to up to $3.01 billion in potential payments. Shares jumped 8% premarket and have gained 500% in the last 12 months, while the S&P 500 SPX, +0.10% has gained 14%. Gilead shares were slightly higher premarket, and have gained 17% in the last 12 months. <<<